EOC Pharma Raises $71 Million in C Round for China Development of In-Licensed Oncology Drugs
publication date: Dec 2, 2019
EOC Pharma, the oncology development arm of China in-licensing company Eddingpharm, raised $71 million in a Series C round led by Tigermed, TF Capital and Yingke PE. Headquartered in Taizhou, EOC manufactures and commercializes oncology products for China use that require mid to late stage clinical development for registration. It currently has a pipeline of six novel products from global biopharmas, including its most recent in-licensing, a Shionogi HER2/EGFR inhibitor intended to treat brain metastasis in advanced metastatic breast cancer patients. Two years ago, EOC completed a $32 million B financing. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.